The Wegovy Injection: In the landmark STEP 1 clinical trial , patients using the 2.4 mg weekly injection lost an average of 14.9% of their body weight over 68 weeks, vs 2.4% with the placebo group
The authors point out that other classes of drugs, including those treating erectile dysfunction and an anti-arrythmic drug, have previously been found to cause NAION in some patients
Richardson AJ, McKain N, Wallace RJ
Benefit 04 Systemic Anti-Inflammatory Effects BPC-157 modulates the COX-2 inflammatory pathway and reduces pro-inflammatory cytokine production
Inadequate hydration amplifies nausea and compounds electrolyte imbalances
Because human studies are limited, doctors do not yet have clear data on the peptide's long-term effects, optimal dosing, potential drug interactions, or safety across different patient populations